| scholarly article | Q13442814 |
| P50 | author | Klaus Friese | Q1282213 |
| Ulrich Andergassen | Q38296409 | ||
| Julia Jückstock | Q38298507 | ||
| P2093 | author name string | Wolfgang Simon | |
| Marion Kiechle | |||
| Arthur Wischnik | |||
| Brigitte Rack | |||
| Philip Hepp | |||
| Thomas Zwingers | |||
| Wolfgang Janni | |||
| Svjetlana Mohrmann | |||
| Doris Augustin | |||
| Alexandra Schönherr | |||
| Jessica Salmen | |||
| Katja Annecke | |||
| Nadja Harbeck | |||
| Viktoria Aivazova-Fuchs | |||
| P2860 | cites work | Taxanes for adjuvant treatment of early breast cancer | Q24242987 |
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group | Q33328841 | ||
| Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial | Q33397151 | ||
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials | Q35740423 | ||
| Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials | Q37038642 | ||
| Obesity and breast cancer: progress to understanding the relationship. | Q37661190 | ||
| Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo | Q40477055 | ||
| Adjuvant docetaxel for high-risk, node-negative breast cancer | Q42788947 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). | Q45918152 | ||
| Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer | Q46133880 | ||
| Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial | Q46443839 | ||
| Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. | Q46493659 | ||
| Adjuvant docetaxel for node-positive breast cancer | Q46522790 | ||
| Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. | Q46573303 | ||
| Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr | Q46624750 | ||
| Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. | Q54071888 | ||
| Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. | Q54156953 | ||
| Benefit of taxanes as adjuvant chemotherapy for early breast cancer | Q61899631 | ||
| Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial | Q66829419 | ||
| Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results | Q68536818 | ||
| Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International | Q70891336 | ||
| NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel | Q73488953 | ||
| Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli | Q77093344 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 289-295 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | Breast Care | Q15764648 |
| P1476 | title | Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer | |
| P478 | volume | 7 |
Search more.